Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients
Autore:
Basara, N; Blau, WI; Kiehl, MG; Schmetzer, B; Bischoff, M; Kirsten, D; Gunzelmann, S; Fauser, AA;
Indirizzi:
Clin Bone Marrow Transplantat & Hematol Oncol, D-55743 Idar Oberstein, Germany Clin Bone Marrow Transplantat & Hematol Oncol Idar Oberstein GermanyD-55743
Titolo Testata:
CLINICAL TRANSPLANTATION
fascicolo: 2, volume: 14, anno: 2000,
pagine: 121 - 126
SICI:
0902-0063(200004)14:2<121:MMFTPO>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; MATCHED UNRELATED DONORS; BLOOD STEM-CELLS; PREVENTION; CYCLOSPORINE; METHOTREXATE; PREDNISONE; RECIPIENTS; CONSENSUS; LEUKEMIA;
Keywords:
bone marrow transplantation; GVHD; mycophenolate mofetil;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Basara, N Clin Bone Marrow Transplantat & Hematol Oncol, Dr Ottmar Kohler Str 2, D-55743 Idar Oberstein, Germany Clin Bone Marrow Transplantat & Hematol Oncol Dr Ottmar Kohler Str 2 Idar Oberstein Germany D-55743
Citazione:
N. Basara et al., "Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients", CLIN TRANSP, 14(2), 2000, pp. 121-126

Abstract

Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in renal and heart transplant recipients, was used in combination with cyclosporin A (CsA), methotrexate (MTX) and prednisolone for the prophylaxis of acute graft-versus-host disease (aGVHD) after bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen (HLA)-mismatched, unrelated (n = 9) and related donors (n = 4) in an open single-centre phase II study. Thirteen patients, transplanted from HLA-mismatched donors of 18-57 yr of age, received 1 g MMF daily, starting at day 10, in addition to CsA and prednisolone for aGVHD prophylaxis. All patients were engrafted between days 13 and 15. Four of the 13 patients experienced aGVHD grade I/II (n = 2) and grade III (n = 2). All patients except 3 were alive on day 100 post-transplantation. No severe adverse effects of MMF were recorded. In our pilot study, we demonstrated that MMF can be used safely for the prophylaxis of aGVHD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 09:45:49